Clinical Trials
3 trialsNCT06573723 2026-01-14
Institutional Registry of Rare Diseases
Hospital Italiano de Buenos Aires
Recruiting
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT00947167 2017-03-03
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Terminated